PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis

Overview of attention for article published in Frontiers in immunology, June 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 9 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 49,194 followers.

RT @GarbineLizeaga: PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analy…

13 Jun 2023

Reply Repost Favourite

RT @GarbineLizeaga: PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analy…

12 Jun 2023

Reply Repost Favourite

Los inhibidores de control inmunitario-ICI, PD1/PDL1, combinadas con quimioterapia mejoraron la PFS de mTNBC, sin embargo, los ICI solo mejoraron la SG en personas con PD-L1+. Mientras se beneficiaba de ICI, sin embargo su tasa de eventos adversos aumento.

12 Jun 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review an…

12 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.